COVID-19 Therapeutics and Treatment

Oral Antiviral

Paxlovid (Nirmatrelvir)

Paxlovid - The Process:

* Complete the form above to determine if you are eligible for treatment

* If you are NOT eligible, our form will let you know.

* If you ARE eligible, you will be able to book a COVID-19 Consultation. There is a non-refundable cost of $49.99 associated with the consult.

* Our pharmacist staff will review your request and then contact you via phone to confirm appropriateness of therapy, and then prescribe treatment (if appropriate)

WHAT IS A MONOCLONAL ANTIBODY?


Monoclonal antibodies (mAb) are a new treatment option for COVID-19 which has been given emergency use authorization (EUA) by the FDA. Monoclonal antibodies are designed in a laboratory to do what our own natural antibodies do, only better. Antibodies are what our body makes on its own to identify and fight infection. The reason we might require treatment with monoclonal antibodies, or mAbs, is that our body may not recognize this new virus SARS-Cov-2 which causes COVID-19. Treatment with mAbs requires direct administration to patients via IV infusion or injection under the skin (subcutaneously). When receiving treatment with mAbs, our bodies can very quickly recognize and fight COVID-19 infection. This is why mAb treatment may help recently exposed or infected patients who are at high risk for serious symptoms or having to stay in the hospital.

mAb treatment for COVID-19 is different from a COVID-19 vaccine. A vaccine causes your body’s natural immune response to turn on, but the process of asking your body to make antibodies or biological markers to identify a certain infection can take weeks. Some vaccines for COVID-19 require two shots, so your body can develop its own immune response to the disease, and these vaccines are highly effective. But if you already have the virus, mAb treatment quickly gives your body the antibodies it needs to protect itself. (1)

Improved

Evusheld

The FDA has removed this product from the market due to the lack of effectiveness against the Omicron variant. This is no longer available any where in the country.

Monoclonal Antibodies

COVID-19 Antibody Treatment (REGEN-COV™)

The FDA has removed this product from the market due to the lack of effectiveness against the Omicron variant. This is no longer available any where in the country.

Works Cited

(1). Assistant Secretary for
Public Affairs (ASPA). “Monoclonal Antibodies for High-Risk COVID-19 Positive
Patients.” CombatCOVID.hhs.gov, 24 Aug. 2021,
https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients.